Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045773 | 0.89 | HTR2C (0.44) | HTR2CHTR2AHTR2BPNMTAVPR1A | |
| SCHEMBL31393901 | 0.85 | AVPR1A (0.42) | HTR2CHTR2AHTR2BAVPR1AOXTR | |
| SCHEMBL21777640 | 0.83 | HTR2C (0.42) | HTR2CHTR2AHTR2BPNMTAVPR1A | |
| SCHEMBL29190476 | 0.83 | SLC6A4 (0.41) | AVPR1AOXTRKDM1AKEAP1NFE2L2 | |
| SCHEMBL30508182 | 0.81 | PNMT (0.41) | HTR2CHTR2AHTR2BPNMTSIGMAR1 | |
| SCHEMBL3745717 | 0.81 | AVPR1A (0.40) | AVPR1AKDM1ASIGMAR1 | |
| SCHEMBL737193 | 0.81 | DPP4 (0.42) | HTR2CHTR2AAVPR1AOXTRSIGMAR1 | |
| SCHEMBL24203780 | 0.79 | AVPR1A (0.44) | AVPR1AOXTRKDM1AKEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL4985671 | 0.79 | AVPR1A (0.39) | AVPR1AKDM1ASIGMAR1 | |
| SCHEMBL24203802 | 0.79 | ATM (0.40) | AVPR1AOXTRKDM1AKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2018-07-31 | — | — | US | claimed |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2017-08-31 | — | — | US | claimed |
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2024-04-18 | — | — | US | disclosed |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210275551-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2021-09-09 | — | — | US | disclosed |
| US-11026957-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| US-20200253995-A1 | METHOD TO TREAT HYPERCHOLESTEROLEMIA BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2020-08-13 | — | — | US | disclosed |
| US-10688114-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SXR Cardio, LLC (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2019115586-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-06-20 | — | — | WO | disclosed |
| US-10307433-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2019-06-04 | — | — | US | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-6509346-B2 | Antiinflammatory agents | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| US-6329385-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, VIRAL DISEASES AND GASTROINTESTINAL DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | HTR2C 672/4885HTR2A 618/4885HTR2B 1659/4885 |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | PCSK9, LDLR, PCSK7 | HTR2C 3890/4885HTR2A 3889/4885HTR2B 3789/4885 |
| US-10307433-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | HTR2C 3873/4885HTR2A 3876/4885HTR2B 3798/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | HTR2C 1811/4885HTR2A 1145/4885HTR2B 1274/4885 |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | HTR2C 3890/4885HTR2A 3889/4885HTR2B 3789/4885 |
| US-20210275551-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | HTR2C 4052/4885HTR2A 3897/4885HTR2B 4046/4885 |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | NFATC1, ELANE, NCF1 | HTR2C 4453/4885HTR2A 4654/4885HTR2B 4452/4885 |
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | HTR2C 4074/4885HTR2A 3892/4885HTR2B 4069/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | HTR2C 3346/4885HTR2A 2903/4885HTR2B 2086/4885 |
| US-20200253995-A1 | METHOD TO TREAT HYPERCHOLESTEROLEMIA BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | HTR2C 3836/4885HTR2A 3832/4885HTR2B 3669/4885 |
| US-11026957-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | PCSK9, LDLR, PCSK7 | HTR2C 4041/4885HTR2A 3883/4885HTR2B 4027/4885 |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | PCSK9, LDLR, PCSK7 | HTR2C 4041/4885HTR2A 3883/4885HTR2B 4027/4885 |
| US-10688114-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | HTR2C 3873/4885HTR2A 3876/4885HTR2B 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.